La nouvelle étude fournit des informations sur la biodisponibilité des formulations de cannabis thérapeutique à des fins thérapeutiques NEW YORK, 27 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, une d ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

H.C. Wainwright 4th Annual Kidney Virtual Conference Date: July 14, 2025 Presentation Time: 3:00 pm CEST / 9:00 am EDT Attendees: Frank Weber, CEO; Julia Neugebauer, COO Virtual conference Link to ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

“Since becoming Evofem’s sourcing partner for PHEXXI in March 2025, we have made rapid and significant progress,” said Jed Latkin, CEO of Windtree Therapeutics. “With this manufacturing contract inked ...

J.P. Morgan, Morgan Stanley, Guggenheim Securities and Cantor acted as joint book-running managers for the offering.

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results ...

The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a ...

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced ...

The securities described above are being offered by CorMedix pursuant to a shelf registration statement on Form S-3 which was initially filed by CorMedix with the Securities and Exchange Commission ...

If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000 clinical trial participants contributed to the body of ...